

CITATION REPORT

List of articles citing

Recommendations for Reporting Cost-effectiveness Analyses

DOI: 10.1001/jama.1996.03540160061034
JAMA - Journal of the American Medical Association,
1996, 276, 1339.

Source: <https://exaly.com/paper-pdf/26816844/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
803	Cost Effectiveness and Quality of Life in Knee Arthroplasty. 1997 , 345, 134-139		100
802	Selection and Use of Vaccines for Healthcare Workers. 1997 , 18, 682-687		8
801	Assessing cost-effectiveness analyses in rheumatoid arthritis and osteoarthritis. 1997 , 10, 413-21		12
800	Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995). 1997 , 12, 685-94		18
799	The generalisability of pharmacoeconomic studies. 1997 , 11, 503-14		32
798	Assessing Outcomes in Population Health: Moving the Field Forward. 1997 , 13, 3-5		14
797	Cost-effectiveness analysis of helicopter EMS for trauma patients. 1997 , 30, 500-6		78
796	A summary of economic evaluations published in the field of rheumatology and related disciplines. 1997 , 40, 1587-93		20
795	Cost-effectiveness analysis and nursing research--is there a fit?. 1998 , 30, 221-2		5
794	Milton Weinstein's insights on the development, use, and methodologic problems in cost-effectiveness analysis. 1998 , 30, 223-7		1
793	Methods for conducting and reporting cost-effectiveness analysis in nursing. 1998 , 30, 229-34		6
792	Cost-effectiveness analysis in the nursing literature, 1992-1996. 1998 , 30, 235-42		11
791	What to consider when conducting a cost-effectiveness analysis in a clinical setting. 1998 , 98, 1149-54		6
790	The effectiveness of cost-effectiveness analysis in containing costs. 1998 , 13, 664-9		84
789	Physician resource utilization in radiation oncology: a model based on management of carcinoma of the prostate. 1998 , 40, 593-603		10
788	Outcomes research in your office. 1998 , 38, 987-9		3
787	The economics of febrile neutropenia: implications for the use of colony-stimulating factors. 1998 , 34, 1857-64		163

786	Cost-effectiveness of tests to assess the risk of sudden death after acute myocardial infarction. 1998 , 31, 1490-2	5
785	Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction. 1998 , 31, 1481-9	6
784	Effectiveness and cost of selective decontamination of the digestive tract in critically ill intubated patients. A randomized, double-blind, placebo-controlled, multicenter trial. 1998 , 158, 908-16	152
783	Cardiac rehabilitation in the elderly. 1998 , 10, 273-83	1
782	A proposal for structured abstracts of health economic studies. 1998 , 32, 1244-6	2
781	Drug therapy: the impact of managed care. 1998 , 44, 1-32	
780	Book Reviews. 1998 , 18, 240-244	2
779	Defining a High-Performance ICU System for the 21st Century: A Position Paper. 1998 , 13, 195-205	18
778	A systematic review of the cost-effectiveness of noncardiac transitional care units. 1998 , 113, 172-7	55
777	A cost-benefit analysis of a cardiovascular disease prevention trial, using folate supplementation as an example. 1998 , 88, 61-7	20
776	Cost-effectiveness analysis in oncology. 1998 , 9, 475-82	25
775	A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group. 1998 , 113, 131-41	129
774	Medical Technology Assessment. 1998 , 87, 1271-1282	5
773	Medical technology assessment: an overview. 1998 , 87, 1271-82	28
772	Economic Aspects of the Perinatal Hospital Stay. 1998 , 25, 483-498	6
771	Interpreting, integrating, and individualizing evidence about the prevention of diabetic nephropathy. 1999 , 131, 707-8	5
770	Cost-effectiveness of treatment for threshold retinopathy of prematurity. 1999 , 104, e47	83
769	Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. 1999 , 16, 499-520	32

768	Outcomes research in critical care: results of the American Thoracic Society Critical Care Assembly Workshop on Outcomes Research. The Members of the Outcomes Research Workshop. 1999 , 160, 358-67	156
767	The effect of acute respiratory distress syndrome on long-term survival. 1999 , 160, 1838-42	82
766	Quality of life and economic evaluation in SLE clinical trials. 1999 , 8, 645-54	34
765	Cervical spine screening with CT in trauma patients: a cost-effectiveness analysis. 1999 , 212, 117-25	248
764	Assessing the cost-effectiveness of postmastectomy radiation therapy. 1999 , 44, 91-8	24
763	Cost-effectiveness analysis of alternative factor VIII products in treatment of haemophilia A. 1999 , 5, 191-202	1
762	Towards a European consensus on conducting and reporting health economic evaluations--a report from the ISPOR Inaugural European Conference. 1999 , 2, 281-7	8
761	What outcomes matter to patients?. 1999 , 14, 357-63	60
760	Cost-effectiveness of the diagnostic evaluation of vertigo. 1999 , 109, 600-5	41
759	A study on the cost effectiveness of sestamibi scintimammography for screening women with dense breasts for breast cancer. 1999 , 55, 243-58	6
758	Economic evaluation of cancer treatments: a review of the methods. 1999 , 11, 78-83	4
757	Shared medical decision-making: a new paradigm for behavioral medicine--1997 presidential address. 1999 , 21, 3-11	31
756	Covariation of physical and mental symptoms across illnesses: results of a factor analytic study. 1999 , 21, 122-7	8
755	Using disease-state management as the key to promoting employer sponsorship of medical nutrition therapy (continuing education credit). 1999 , 99, 583-8; quiz 589-90	3
754	Economic consequences of the progression of rheumatoid arthritis in Sweden. 1999 , 42, 347-56	139
753	Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. 1999 , 8, 203-11	40
752	Cost-effectiveness in Health and Medicine. By M.R. Gold, J.E Siegel, L.B. Russell, and M.C. Weinstein (eds). New York: Oxford University Press, 1996. 1999 , 2, 91-92	33
751	Measuring costs of guideline-driven mental health care: the Texas Medication Algorithm Project. 1999 , 2, 111-121	19

750	Costs and Benefits of Prevention and Disease Management. 1999 , 5, 153-166	20
749	Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine. 1999 , 19, 371-7	82
748	Raising the quality of cost-utility analyses: lessons learnt and still to learn. 1999 , 46, 217-38	42
747	Costing vascular surgery: A review of current reporting practice. 1999 , 30, 668-78	2
746	Cost-effectiveness of stress-echocardiography. 1999 , 17, 583-95, x	1
745	Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure?. 1999 , 74, 559-64	4
744	Prospective randomized trial comparing the outcome and cost of in vitro fertilization with that of a traditional treatment algorithm as first-line therapy for couples with infertility. 1999 , 71, 468-75	99
743	Resampling and multiplicity in cost-effectiveness inference. 1999 , 9, 563-82	22
742	Finding answers to questions using cost analysis. 1999 , 70, 128-30	2
741	Health care worker disability due to latex allergy and asthma: a cost analysis. 1999 , 89, 1024-8	44
740	A systematic review of cost-effectiveness research of stroke evaluation and treatment. 1999 , 30, 1340-9	61
739	Is the societal perspective in cost-effectiveness analysis useful for decision makers?. 1999 , 25, 447-54	22
738	Systematic overview of cost-utility assessments in oncology. 2000 , 18, 3302-17	253
737	Hepatic resection for colorectal liver metastases: A cost-effectiveness analysis. 2000 , 232, 763-76	45
736	Economic aspects of peripheral arterial disease. 2000 , 19, S39-S46	
735	Economic evaluation of alcohol treatment services. 2000 , 23, 27-39	38
734	Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. 2000 , 31, 1019-21	335
733	Cost reduction and quality improvement: it takes two to tango. 2000 , 28, 581-3	25

732	Assessing the quality of economic evaluations of health care interventions. 2000 , 11, 1513-5	2
731	Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. 2000 , 11, 1591-5	32
730	Economic Burden of Hospitalizations for Preterm Labor in the United States. 2000 , 96, 95-101	4
729	Costing interventions in primary care. 2000 , 17, 66-70	11
728	The FDA's regulation of health economic information. 2000 , 19, 129-37	33
727	Conference report: Oncology pharmacoeconomics The Seventh International Symposium on Oncology Pharmacy Practice, Prague, Czech Republic, April 5-8, 2000. 2000 , 6, 126-129	
726	Cost-utility analyses of clinical preventive services: published ratios, 1976-1997. 2000 , 19, 15-23	73
725	Costs for acute myocardial infarction in a tertiary care centre and nationwide in France. 2000 , 17, 603-9	11
724	Economic aspects of peripheral arterial disease. 2000 , 31, S45-S53	
723	Comparative cost effectiveness of varicella, hepatitis A, and pneumococcal conjugate vaccines. 2001 , 33, 639-45	20
722	Critical issues in the economic evaluation of interventions against communicable diseases. 2001 , 78, 191-206	18
721	Accuracy of terminology and methodology in economic analyses in otolaryngology. 2001 , 124, 496-502	19
720	Decision analysis and its application in clinical medicine. 2001 , 94, 172-9	11
719	The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. 2001 , 357, 1191-1194	3009
718	Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses. 2001 , 1, 25-36	71
717	Cost-Effectiveness Analyses: A Basic Overview for Dermatologists. 2001 , 5, 217-222	1
716	Economics of end-of-life care in the intensive care unit. 2001 , 29, N46-51	52
715	Cost analysis of vaginal birth after cesarean. 2001 , 44, 571-87	5

714	Getting closer to the truth: overcoming research challenges when estimating the financial impact of worksite health promotion programs. 2001 , 15, 289-95	19
713	Economic analysis of randomized, controlled trials. 2001 , 3, 396-403	5
712	Renewal of our value in health mission and policy as we enter our fourth year. 2001 , 4, 1-4	
711	Twenty years of health care economic analysis in Spain: are we doing well?. 2001 , 10, 715-29	19
710	Strategies for diagnosing and treating suspected acute bacterial sinusitis: a cost-effectiveness analysis. 2001 , 16, 701-11	33
709	[Analysis of the medico-economic literature comparing primary angioplasty and thrombolysis in the management of acute myocardial infarction]. 2001 , 50, 330-9	
708	Understanding economic analyses. 2001 , 2, 2-5	7
707	The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. 2001 , 1, 2	537
706	Cost-effectiveness of colorectal cancer screening. 2001 , 219, 44-50	29
705	Cost-effectiveness analysis in radiology. 2001 , 219, 611-20	57
704	The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program. 2001 , 164, 2057-66	43
703	Decision analysis: a basic overview for the pediatric surgeon. 2002 , 11, 46-54	3
702	Abdominal aortic aneurysms: cost-effectiveness of elective endovascular and open surgical repair. 2002 , 225, 337-44	51
701	Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research. 2002 , 165, 540-50	141
700	Cost-Effective Analysis. 2002 , 3, 212-217	
699	An update on cost-effectiveness analysis in critical care. 2002 , 8, 337-43	52
698	A cost-utility analysis of interventions for severe proliferative vitreoretinopathy. 2002 , 133, 365-72	46
697	Standardisation of costs: the Dutch Manual for Costing in economic evaluations. 2002 , 20, 443-54	258

696	A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000. 2002 , 30, 145-52	143
695	Do HEDIS measures reflect cost-effective practices?. 2002 , 23, 276-89	15
694	Paying for prevention standardizing the measurement of the value of health care interventions. 2002 , 29, 613-43, v	
693	Cost-Effectiveness of Venous Thromboembolism Prophylaxis after Total Hip Replacement. 2002 , 17, 126-133	4
692	Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma. 2002 , 22, 479-85	9
691	Pharmaco-economics of blood transfusion safety: review of the available evidence. 2002 , 83, 146-55	51
690	Prophylactic cranial irradiation revisited: cost-effectiveness and quality of life in small-cell lung cancer. 2002 , 52, 68-74	25
689	Economic evaluation in long-term clinical trials. 2002 , 21, 2879-88	10
688	Empiric beta-blockers for the prophylaxis of variceal hemorrhage: cost effective or clinically applicable?. 2003 , 37, 249-52	4
687	The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. 2003 , 7, 2-7	123
686	Pharmacoeconomics of lipid-lowering drugs. 2003 , 5, 67-72	
685	Cost-effectiveness of intracoronary ultrasound for percutaneous coronary interventions. 2003 , 91, 143-7	23
684	Decision science and cervical cancer. 2003 , 98, 2003-8	12
683	The impact of including passive benefits in cost-effectiveness analysis: the case of automated external defibrillators on commercial aircraft. 2003 , 6, 466-73	9
682	The Pediatric Quality Appraisal Questionnaire: an instrument for evaluation of the pediatric health economics literature. 2003 , 6, 584-94	37
681	The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. 2003 , 43, 721-9	193
680	Evidence-based ethics and the care and outcome of extremely premature infants. 2003 , 30, 363-87	59
679	Cost-effectiveness of testing for human immunodeficiency virus and hepatitis C virus among blood transfusion recipients. 2003 , 24, 132-6	2

678	34th Bethesda Conference: Task force #5--Is atherosclerosis imaging cost effective?. 2003 , 41, 1906-17	39
677	Cost-effectiveness of helicopter transport of stroke patients for thrombolysis. 2003 , 10, 966-72	57
676	A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. 2003 , 25, 611-34	26
675	Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. 2003 , 14, S395-404	136
674	Die Kosteneffektivität von Amlodipin in der Behandlung der koronaren Atherosklerose in Österreich. 2003 , 1, 39-48	
673	Sedating patients undergoing mechanical ventilation in the intensive care unit--winds of change?. 2003 , 90, 267-9	16
672	Atherosclerotic and hemostatic abnormalities in patients undergoing hemodialysis. 2003 , 9, 53-60	11
671	Effects of lipid abnormalities on arteriosclerosis and hemostatic markers in patients under hemodialysis. 2003 , 9, 203-10	7
670	Chapter 15: Public health policy and cost-effectiveness analysis. 2003 , 102-10	33
669	Prevention of Herpes Simplex Virus Eye Disease: A Cost-Effectiveness Analysis. 2003 , 4, 104-105	
668	New Choices for Central Venous Catheters. 2003 , 124, 275-284	60
667	Cost-effective Antiemesis. 2003 , 41, 145-64	7
666	Should radon be reduced in homes? A cost-effect analysis. 2003 , 84, 227-35	19
665	Economic evaluation of new therapies in critical illness. 2003 , 31, S7-16	52
664	It is money that matters: decision analysis and cost-effectiveness analysis. 2003 , 106-16	23
663	Quantitative analysis of sponsorship bias in economic studies of antidepressants. 2003 , 183, 498-506	103
662	Cost-Effectiveness of Testing for Human Immunodeficiency Virus And Hepatitis C Virus Among Blood Transfusion Recipients. 2003 , 24, 132-136	1
661	Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection. 2004 , 233, 729-39	45

660	Quality of abstracts describing randomized trials in the proceedings of American Society of Clinical Oncology meetings: guidelines for improved reporting. 2004 , 22, 1993-9	43
659	Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain. 2004 , 7, 52-60	28
658	Use of B-type natriuretic peptide for the management of women with dyspnea. 2004 , 94, 1510-4	38
657	Design, execution, interpretation, and reporting of economic evaluation studies in obstetrics. 2004 , 191, 1070-6	41
656	Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. 2004 , 124, 507-17	52
655	Cost-effectiveness of losartan versus atenolol in treating hypertension--an analysis of the LIFE study from a Swiss perspective. 2004 , 18, 391-7	8
654	Chronic obstructive pulmonary disease: is there a case for early intervention?. 2004 , 117 Suppl 12A, 3S-10S	5
653	The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. 2004 , 50, 129-46	59
652	Cost-utility analysis for endoscopic sinus surgery. 2004 , 130, 31-8	17
651	The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis. 2004 , 116, 451-9	22
650	Economic evaluation in total hip arthroplasty: analysis and review of the literature. 2004 , 19, 180-9	78
649	Is a charge a cost if nobody pays it?. 2004 , 126, 662-4	
648	Cost-effectiveness of lumbar fusion and nonsurgical treatment for chronic low back pain in the Swedish Lumbar Spine Study: a multicenter, randomized, controlled trial from the Swedish Lumbar Spine Study Group. 2004 , 29, 421-34; discussion Z3	103
647	Oral decontamination is cost-saving in the prevention of ventilator-associated pneumonia in intensive care units. 2004 , 32, 126-30	60
646	Cost-utility and cost-benefit analyses: how did we get here and where are we going?. 2004 , 16, 527-34	23
645	Decision analysis and economic modelling: a primer. 2004 , 16, 535-42	32
644	Health care economic analyses. 2004 , 24, 139-46	15
643	Cost-effectiveness of a trial of labor after previous cesarean delivery depends on the a priori chance of success. 2004 , 47, 378-85	5

642	Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls. 2004 , 16, 519-26	27
641	COST-UTILITY ANALYSIS: THE FOUNDATION OF VALUE-BASED MEDICINE—CATARACT SURGERY IN THE SECOND EYE. 2004 , 5, 112-120	1
640	COST-UTILITY ANALYSIS: THE FOUNDATION OF VALUE-BASED MEDICINE—THE DRAMATIC EFFECT OF DISCOUNTING. 2004 , 5, 180-184	
639	Economic evaluation of a comprehensive self-management programme in patients with moderate to severe chronic obstructive pulmonary disease. 2004 , 1, 7-16	35
638	BARRETT ESOPHAGUS: MORE QUESTIONS THAN ANSWERS. 2005 , 6, 4-6	
637	Practical clinical trials for translating research to practice: design and measurement recommendations. 2005 , 43, 551-7	264
636	Five-year survival, quality of life, and individual costs of 303 consecutive medical intensive care patients—a cost-utility analysis. 2005 , 33, 547-55	56
635	Cost-Effectiveness of Bupropion, Nortriptyline, and Psychological Intervention in Smoking Cessation. 2005 , 32, 381-392	
634	Early discharge from obstetrics-pediatrics at the Hospital de Valme, with domiciliary follow-up. 2005 , 193, 714-26	28
633	The evaluation of rectal bleeding in adults. A cost-effectiveness analysis comparing four diagnostic strategies. 2005 , 20, 81-90	15
632	Intrarace differences among black and white americans presenting for chronic pain management: the influence of age, physical health, and psychosocial factors. 2005 , 6, 29-38	59
631	B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison. 2005 , 67, 278-84	51
630	Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. 2005 , 8, 521-33	481
629	Growth and quality of the cost-utility literature, 1976-2001. 2005 , 8, 3-9	114
628	Cost-effectiveness of leucocyte-depleted erythrocyte transfusion in cardiac valve surgery. 2005 , 15, 209-17	7
627	Capecitabine plus docetaxel combination therapy. 2005 , 103, 2455-65	20
626	[CONSORT statement. Revised findings on quality improvement based on reports from randomized studies in parallel design]. 2005 , 19, 156-62	3
625	Medizinische Ökonomie in der Onkologie. 2005 , 11, 139-151	

624	Cost-effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation. 2005 , 32, 381-92	39
623	Quality appraisal of pediatric health economic evaluations. 2005 , 21, 203-210	19
622	Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. 2005 , 112, 3745-53	32
621	Quality of abstracts of papers reporting original cost-effectiveness analyses. 2005 , 25, 424-8	25
620	Decision analysis and simulation modeling for evaluating diagnostic tests on the basis of patient outcomes. 2005 , 185, 581-90	13
619	Economic study in surgical patients of a new model of nutrition therapy integrating hospital and home vs the conventional hospital model. 2005 , 29, S96-105	10
618	Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans. 2005 , 23, 8877-83	31
617	A synthesis of cost-utility analysis literature in infectious disease. 2005 , 5, 383-91	15
616	The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials 2001. 2005 , 1, 40-5	124
615	Cost-utility analysis of tympanomastoidectomy for adults with chronic suppurative otitis media. 2005 , 133, 352-6	9
614	The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data. 2005 , 140, 679-87	42
613	Radiology cost and outcomes studies: standard practice and emerging methods. 2005 , 185, 833-9	28
612	Cost-effectiveness analysis in the assessment of diagnostic imaging technologies. 2005 , 235, 361-70	59
611	Quality-of-life valuations of advanced breast cancer by New Zealand women. 2006 , 24, 415-6; author reply 416-7	2
610	Preoperative use of mupirocin for the prevention of healthcare-associated Staphylococcus aureus infections: a cost-effectiveness analysis. 2006 , 27, 1304-12	33
609	Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. 2006 , 151, 471-7	52
608	Economic analysis in hand surgery. 2006 , 31, 664-8	7
607	Cost-Effectiveness of Single- Versus Double-Cylinder Over-Water Nest Structures. 2006 , 34, 647-655	2

606	Cost-effectiveness analysis of sedation and analgesia regimens during fracture manipulation in the pediatric emergency department. 2006 , 22, 729-36	18
605	56,000 Ways? No way!. 2006 , 17, 219-22	
604	A cost/utility analysis of open reduction and internal fixation versus cast immobilization for acute nondisplaced mid-waist scaphoid fractures. 2006 , 117, 1223-35; discussion 1236-8	79
603	Is cataract surgery cost-effective among older patients with a low predicted probability for improvement in reported visual functioning?. 2006 , 44, 982-9	22
602	Trends in the measurement of health utilities in published cost-utility analyses. 2006 , 9, 213-8	102
601	Investigating postmenopausal bleeding for endometrial cancer: cost-effectiveness of initial diagnostic strategies. 2006 , 113, 502-10	80
600	Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. 2006 , 94, 1122-9	101
599	The association between symptom burdens and utility in Chinese cancer patients. 2006 , 15, 1427-38	11
598	A review of health care models for coronary heart disease interventions. 2006 , 9, 311-24	19
597	Economic evaluations: a new avenue of outcome assessment in spinal disorders. 2006 , 15 Suppl 1, S109-17	21
596	The use of B-type natriuretic peptide in the management of patients with diabetes and acute dyspnoea. 2006 , 49, 629-36	6
595	Peripheral arterial disease: clinical and cost comparisons between duplex US and contrast-enhanced MR angiography--a multicenter randomized trial. 2006 , 240, 401-10	30
594	Quality assessment of published health economic analyses from South America. 2006 , 40, 943-9	13
593	Cost-effectiveness of drug-eluting stents: real-world scrutiny of the BASKET trial of real-world usage. 2006 , 3, 305-9	2
592	Lumbar disc disorders and low-back pain: socioeconomic factors and consequences. 2006 , 88 Suppl 2, 21-4	909
591	In Reply. 2006 , 24, 5616-5616	3
590	An economic analysis of the timing of microsurgical reconstruction in brachial plexus birth palsy. 2007 , 89, 970-8	16
589	N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. 2007 , 115, 3103-10	251

588	Strategies to prevent varicella among newly arrived adult immigrants and refugees: a cost-effectiveness analysis. 2007 , 44, 1040-8	23
587	Simplified pharmacoeconomics of critical care and severe sepsis. 2007 , 22, 283-93	3
586	Quality-of-life assessment when there is a loss of income. 2007 , 27, 27-33	14
585	Interpreting the economic literature in oncology. 2007 , 25, 196-202	24
584	Estimating preference scores in conventional and home nocturnal hemodialysis patients. 2007 , 2, 477-83	10
583	M20-01: The cost of care for patients with lung cancer. 2007 , 2, S209-S210	
582	Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. 2007 , 105, 1615-28, table of contents	478
581	Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis. 2007 , 18, 309-16	24
580	Methodologic quality of cost-effectiveness analyses of surgical procedures. 2007 , 245, 147-51	20
579	Influence of economic evaluations on public health policy. 2007 , 18, 28-32	2
578	Pharmacoeconomics and macular degeneration. 2007 , 18, 206-11	2
577	Who Pays the Piper?. 2007 , 41, S97-S101	3
576	Health services research methods: tools for nurse leaders. 2007 , 31, 304-11	1
575	Utilizaci3n de los datos farmacoecon3micos en la inclusi3n de un nuevo medicamento en el formulario o gu3a farmacoterap3utica hospitalaria: ¿por qu3y de qu3manera?. 2007 , 4, 109-112	
574	Choice of modelling technique for evaluating health care interventions. 2007 , 58, 168-176	45
573	Tools for Assessment of Cardiovascular Tests and Therapies. 2007 , 1-34	
572	Association of hospital and surgeon procedure volume with patient-centered outcomes of total knee replacement in a population-based cohort of patients age 65 years and older. 2007 , 56, 568-74	131
571	Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. 2007 , 110, 489-98	86

570	Assessing differences in utility scores: a comparison of four widely used preference-based instruments. 2007 , 10, 256-65	43
569	The value of health care--a matter of discussion in Germany. 2007 , 7, 1	122
568	A cost-utility analysis of treatments for malignant liver tumours: a pilot project. 2007 , 9, 42-51	3
567	Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. 2007 , 23, 229-36	7
566	Screening for syphilis in pregnancy: which is the proper method?. 2007 , 276, 629-31	7
565	Improving colorectal cancer screening among the medically underserved: a pilot study within a federally qualified health center. 2007 , 22, 1410-4	85
564	Cost-effectiveness of primary cytology and HPV DNA cervical screening. 2008 , 122, 372-6	13
563	Pharmacoeconomics is coming of age. 2008 , 84, 188-90	2
562	Universal ureteral stent placement at hysterectomy to identify ureteral injury: a decision analysis. 2008 , 115, 1151-8	45
561	Quality-initiated prophylactic antibiotic use in laparoscopic-assisted vaginal hysterectomy. 2008 , 48, 592-5	14
560	The cost-effectiveness of a behavior intervention with caregivers of patients with Alzheimer's disease. 2008 , 56, 413-20	85
559	Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). 2008 , 63 Suppl 86, 8-160	2973
558	Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications. 2008 , 8, 270	144
557	Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?. 2008 , 58, 231-44	65
556	Cost-Effectiveness of B-Type Natriuretic Peptide Testing. 2008 , 14, 35-37	8
555	Cost-effectiveness of B-type natriuretic peptide testing. 2008 , 14, 35-7	4
554	A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. 2008 , 115, 1039-1045.e5	74
553	Cambios en el valor de la utilidad dependiendo del método empleado en su medicina y del país y cultura donde se haya obtenido: ¿cómo pueden afectar a los resultados de los análisis coste-utilidad?. 2008 , 5, 67-70	

552	Cost-effectiveness of rapid point-of-care prenatal syphilis screening in sub-Saharan Africa. 2008 , 35, 775-84	47
551	Twenty years of cost-effectiveness analysis in medical imaging: are we improving?. 2008 , 249, 917-25	37
550	Proposal for the development of a standardized protocol for assessing the economic costs of HIV prevention interventions. 2008 , 47 Suppl 1, S10-4	1
549	Cost-effectiveness analysis of periacetabular osteotomy. 2008 , 90, 1447-56	41
548	Mathematical models and health economic aspects of microbicides. 2008 , 3, 587-92	7
547	Utilities should not be multiplied: evidence from the preference-based scores in the United States. 2008 , 46, 984-90	37
546	Using observational data for decision analysis and economic analysis. 2009 , 91 Suppl 3, 73-9	19
545	How can reporting guidelines help you write your research findings?. 2009 , 56, 5-9	7
544	The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study. 2009 , 29, 224-38	32
543	CT coronary angiography in patients suspected of having coronary artery disease: decision making from various perspectives in the face of uncertainty. 2009 , 253, 734-44	54
542	Evaluating eHealth: undertaking robust international cross-cultural eHealth research. 2009 , 6, e1000105	22
541	Cost, effectiveness, and cost-effectiveness. 2009 , 2, 49-54	27
540	THE COMPARATIVE EFFECTIVENESS AND COST-EFFECTIVENESS OF INTRAOCULAR 90Sr BRACHYTHERAPY/INTRAVITREAL VEGF INHIBITOR FOR NEOVASCULAR MACULAR DEGENERATION. 2009 , 10, 107-122	16
539	Decision Analysis and Cost-effectiveness Analysis. 2009 , 21, 216-222	28
538	Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. 2009 , 115, 5450-9	48
537	Technology and the issue of cost/benefit in diabetes. 2009 , 25 Suppl 1, S34-44	17
536	Cost utility analysis of knee prosthesis with complete microprocessor control (C-leg) compared with mechanical technology in trans-femoral amputees. 2009 , 10, 47-55	47
535	Vancomycin flush as antibiotic prophylaxis for early catheter-related infections: a cost-effectiveness analysis. 2009 , 17, 285-93	2

534	Cost effectiveness of internet interventions: review and recommendations. 2009 , 38, 40-5	185
533	Case reports describing treatments in the emergency medicine literature: missing and misleading information. 2009 , 9, 10	29
532	A cost-effectiveness analysis of a multimedia learning education program for stoma patients. 2010 , 19, 1844-54	21
531	Assessment of transparency of cost estimates in economic evaluations of patient safety programmes. 2009 , 15, 451-9	27
530	Cost-effectiveness of screening for unhealthy alcohol use with % carbohydrate deficient transferrin: results from a literature-based decision analytic computer model. 2009 , 33, 1440-9	13
529	Surveying clinical surveys. 2009 , 116, 1285-9	7
528	Ultrasound-guided central line placement as compared with standard landmark technique: some unpleasant arithmetic for the economics of medical innovation. 2009 , 12, 98-100	7
527	The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. 2009 , 12, 1086-99	55
526	Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. 2009 , 27, 4891-904	45
525	Cost-utility analysis of screening and laser treatment of retinopathy of prematurity. 2009 , 13, 186-90	24
524	The use of B-type natriuretic peptide in the management of patients with atrial fibrillation and dyspnea. 2009 , 136, 193-9	9
523	Induced cardiovascular procedural costs and resource consumption patterns after coronary artery calcium screening: results from the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) study. 2009 , 54, 1258-67	44
522	A cost-utility analysis of ablative therapy for Barrett's esophagus. 2009 , 136, 2101-2114.e1-6	149
521	Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan. 2009 , 27, 597-608	15
520	30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. 2009 , 27, 861-72	56
519	Comparative effectiveness: its role in the healthcare system. 2009 , 20, 188-94	7
518	Cost-Effectiveness of B-Type Natriuretic Peptide in the Management of Dyspnea. 2009 , 16, 199-201	
517	Reducing hospital expenditures with the COPE (Creating Opportunities for Parent Empowerment) program for parents and premature infants: an analysis of direct healthcare neonatal intensive care unit costs and savings. 2009 , 33, 32-7	58

516	The economics of minimally invasive spine surgery: the value perspective. 2010 , 35, S375-82	49
515	Fundamental principles of conducting a surgery economic analysis study. 2010 , 125, 727-735	31
514	Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. 2010 , 54, 258-68	49
513	Consensus guidelines in the management of branch duct intraductal papillary mucinous neoplasm: a cost-effectiveness analysis. 2010 , 55, 852-60	30
512	The cost-effectiveness of prenatal screening for spinal muscular atrophy. 2010 , 202, 253.e1-7	32
511	International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?. 2010 , 19, 422-37	465
510	Grading Economic Evidence. 2010 , 114-133	5
509	Cost-effectiveness of strategies for diagnosing pulmonary embolism among emergency department patients presenting with undifferentiated symptoms. 2010 , 56, 321-332.e10	28
508	The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. 2010 , 50, 2461-73	54
507	Cost-effectiveness analysis in infectious diseases. 2010 , 16, 1705-6	1
506	Modeling health care policy alternatives. 2010 , 45, 1541-58	13
505	Validation and comparison of EuroQol and short form 6D in chronic prostatitis patients. 2010 , 13, 649-56	40
504	Economic evaluation and transferability of physical activity programmes in primary prevention: a systematic review. 2010 , 7, 1622-48	14
503	Predicting utility for joint health states: a general framework and a new nonparametric estimator. 2010 , 30, E29-39	28
502	Single-dose versus multiple-dose antibiotic prophylaxis for the surgical treatment of closed fractures. 2010 , 81, 256-62	25
501	Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. 2010 , 11, 248-59	12
500	Suspected carotid artery stenosis: cost-effectiveness of CT angiography in work-up of patients with recent TIA or minor ischemic stroke. 2010 , 256, 585-97	28
499	Minor head injury: CT-based strategies for management--a cost-effectiveness analysis. 2010 , 254, 532-40	70

498	CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. 2010 , 63, e1-37	1234
497	Economic effects of pharmacists on health outcomes in the United States: A systematic review. 2010 , 67, 1624-34	102
496	Estimation of a valuation function for a diabetes mellitus-specific preference-based measure of health: the Diabetes Utility Index. 2010 , 28, 201-16	10
495	Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. 2010 , 28, 521-38	28
494	Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. 2010 , 14, 375-84	36
493	Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals. 2011 , 58, 1690-701	56
492	Utility-based quality of life of overweight and obese adolescents. 2011 , 14, 752-8	14
491	Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. 2011 , 4, 9-22	131
490	Cost-effectiveness analysis of the most common orthopaedic surgery procedures: knee arthroscopy and knee anterior cruciate ligament reconstruction. 2011 , 27, 1317-22	78
489	Incremental cost-utility analysis of deep anterior lamellar keratoplasty compared with penetrating keratoplasty for the treatment of keratoconus. 2011 , 152, 40-47.e2	31
488	An economic analysis of outcomes and complications of treating distal radius fractures in the elderly. 2011 , 36, 1912-8.e1-3	73
487	Development of an activity-based costing model to evaluate physician office practice profitability. 2011 , 118, 203-208.e1-3	11
486	Comparative effectiveness and cost-effectiveness of the implantable miniature telescope. 2011 , 118, 1834-43	21
485	Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease. 2011 , 6, e24870	29
484	Dollars and sense in sepsis. 2011 , 39, 1559-60	
483	The tale of two serologic tests to screen for syphilis--treponemal and nontreponemal: does the order matter?. 2011 , 38, 448-56	20
482	Cost-effectiveness of an emergency department-based early sepsis resuscitation protocol. 2011 , 39, 1306-12	44
481	Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?. 2011 , 13, 783-91	22

480	Spinal cord stimulation versus re-operation in patients with failed back surgery syndrome: an international multicenter randomized controlled trial (EVIDENCE study). 2011 , 14, 330-5; discussion 335-6	65
479	Comparing behavioral weight loss modalities: incremental cost-effectiveness of an internet-based versus an in-person condition. 2011 , 19, 1629-35	70
478	Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disorders. 2011 , 19 Suppl 1, S6-44	60
477	Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. 2011 , 104, 1377-83	26
476	Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. 2011 , 63, 65-78	62
475	Cost-effectiveness of screening for abdominal aortic aneurysm in the Netherlands and Norway. 2011 , 98, 1546-55	35
474	Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer. 2011 , 127, e279-86	50
473	Economic evaluation of caffeine for apnea of prematurity. 2011 , 127, e146-55	31
472	Cost-Effectiveness Analysis of Unicompartmental Knee Arthroplasty and High Tibial Osteotomy for Treatment of Medial Compartmental Osteoarthritis. 2011 , 1, 27-37	3
471	Pathologic evaluation of routine pediatric tonsillectomy specimens: analysis of cost-effectiveness. 2011 , 144, 778-83	18
470	Quality-of-life implications of immediate surgery and watchful waiting in asymptomatic aortic stenosis: a decision-analytic model. 2011 , 4, 541-8	8
469	Serologic testing for syphilis in the United States: a cost-effectiveness analysis of two screening algorithms. 2011 , 38, 1-7	62
468	Economic Evaluation With Clinical Trials in Neonatology. 2011 , 12, e69-e75	6
467	Reporting standards for studies of tailored interventions. 2012 , 27, 331-42	44
466	Preference-based comparative effectiveness and cost-effectiveness: a review and relevance of value-based medicine for vitreoretinal interventions. 2012 , 23, 163-74	9
465	Average cost-effectiveness ratio with censored data. 2012 , 22, 401-15	18
464	The co-occurrence of reading disorder and ADHD: epidemiology, treatment, psychosocial impact, and economic burden. 2012 , 45, 538-64	88
463	Clinical trials in orthopaedics research. Part III. Overcoming operational challenges in the design and conduct of randomized clinical trials in orthopaedic surgery. 2012 , 94, e35	15

462	The combined use of surgery and radiotherapy to treat patients with epidural cord compression due to metastatic disease: a cost-utility analysis. 2012 , 14, 631-40	30
461	Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. 2012 , 43, 881-3	85
460	Second-look endoscopy for bleeding peptic ulcer disease: a decision-effectiveness and cost-effectiveness analysis. 2012 , 46, e71-5	19
459	Perspectives on cost-effective medicine and the use of cost-effectiveness analyses. 2012 , 54, 2-3	3
458	Cost analysis and provider satisfaction with pediatrician in triage. 2012 , 28, 971-6	8
457	Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. 2012 , 56, 2172-9	31
456	The Irritable Bowel Syndrome Outcome Study (IBSOS): rationale and design of a randomized, placebo-controlled trial with 12 month follow up of self- versus clinician-administered CBT for moderate to severe irritable bowel syndrome. 2012 , 33, 1293-310	33
455	CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. 2012 , 10, 28-55	1007
454	The economics of antimicrobial stewardship: the current state of the art and applying the business case model. 2012 , 33, 389-97	21
453	Acellular dermal matrices: economic considerations in reconstructive and aesthetic breast surgery. 2012 , 39, 187-216	19
452	Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy. 2012 , 53, 2371-7	21
451	Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. 2012 , 56, 1089-1096	48
450	Median-Based Incremental Cost-Effectiveness Ratio (ICER). 2012 , 6, 428-442	42
449	The cost effectiveness of radiofrequency ablation for Barrett's esophagus. 2012 , 143, 567-575	124
448	Coronary CT angiography versus myocardial perfusion imaging for near-term quality of life, cost and radiation exposure: a prospective multicenter randomized pilot trial. 2012 , 6, 274-83	55
447	Reporting guidelines: optimal use in preventive medicine and public health. 2012 , 43, e31-42	9
446	The cost-effectiveness of total joint arthroplasty: a systematic review of published literature. 2012 , 26, 649-58	196
445	Informing shared decisions about advance directives for patients with severe chronic obstructive pulmonary disease: a modeling approach. 2012 , 15, 357-66	5

444	Cost-effectiveness analysis of primary arthroscopic stabilization versus nonoperative treatment for first-time anterior glenohumeral dislocations. 2012 , 28, 1755-65	49
443	Design of a trial to evaluate the impact of clinical pharmacists and community health promoters working with African-Americans and Latinos with diabetes. 2012 , 12, 891	20
442	Economic analysis of alvimopan for prevention and management of postoperative ileus. 2012 , 32, 120-8	22
441	Attention: Minimal hepatic encephalopathy and road accidents. 2012 , 55, 985-7	7
440	Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. 2012 , 18, 1608-16	32
439	Economic methods in the century trial--a comprehensive lifestyle modification study for managing coronary artery disease. 2012 , 5, 333-6	2
438	SF-6D and EQ-5D result in widely divergent incremental cost-effectiveness ratios in a clinical trial of older women: implications for health policy decisions. 2012 , 23, 1849-57	20
437	Implementing evidence-based changes in emergency department treatment: alternative vitamin therapy for alcohol-related illnesses. 2012 , 59, 408-12	5
436	B-type natriuretic peptide in the evaluation and management of dyspnoea in primary care. 2012 , 272, 504-13	22
435	Econometric studies on pharmacist care services are lacking--a call for papers. 2012 , 20, 69-70	
434	Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. 2012 , 118, 1119-29	49
433	Cost-effectiveness analyses of training: a manager's guide. 2013 , 11, 20	2
432	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. 2013 , 11, 6	230
431	Patient-reported outcomes in the practice-based opportunities for weight reduction (POWER) trial. 2013 , 22, 2389-98	20
430	A comparison of the ICECAP-O with EQ-5D in a falls prevention clinical setting: are they complements or substitutes?. 2013 , 22, 969-77	69
429	How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists. 2013 , 59, 257-64	108
428	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. 2013 , 11, 80	151
427	Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. 2013 , 16, 231-50	1264

426	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. 2013 , 31, 361-7	90
425	Cost-effectiveness analysis for imaging techniques with a focus on cardiovascular magnetic resonance. 2013 , 15, 52	17
424	The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective. 2013 , 16, 334-44	18
423	The price of emergency contraception in the United States: what is the cost-effectiveness of ulipristal acetate versus single-dose levonorgestrel?. 2013 , 87, 385-90	15
422	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. 2013 , 16, e1-5	381
421	Cost-utility of rapid polymerase chain reaction-based influenza testing for high-risk emergency department patients. 2013 , 62, 80-8	22
420	Cataract surgery cost utility revisited in 2012: a new economic paradigm. 2013 , 120, 2367-2376	70
419	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. 2013 , 35, 356-63	14
418	Cost-effectiveness of liver cancer screening. 2013 , 27, 961-72	27
417	The AViKA (Adding Value in Knee Arthroplasty) postoperative care navigation trial: rationale and design features. 2013 , 14, 290	8
416	Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective. 2013 , 11, 219-36	15
415	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. 2013 , 14, 367-72	136
414	The validity and responsiveness of the EQ-5D measure of health-related quality of life in an adolescent population with persistent major depression. 2013 , 22, 101-10	21
413	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. 2013 , 120, 765-70	25
412	Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. 2013 , 108, 120-32	86
411	Cost-effectiveness of gene-expression profiling for tumor-site origin. 2013 , 16, 46-56	2
410	Functional disorders of the gastrointestinal tract: Cost effectiveness review. 2013 , 27, 913-31	12
409	Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. 2013 , 59, 300-7	242

408	Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. 2013 , 11, 1158-66	32
407	Economic evaluation studies in reproductive medicine: a systematic review of methodologic quality. 2013 , 99, 1689-94	8
406	Cost-effectiveness analysis of a pertussis vaccination programme for Japan considering intergenerational infection. 2013 , 31, 2891-7	3
405	How to value technological innovation: a proposal for determining relative clinical value. 2013 , 144, 5-8	5
404	Pharmaceutical utilisation and costs before and after bariatric surgery. 2013 , 37, 1467-72	14
403	Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?. 2013 , 21, 655-67	44
402	Systematic review and quality assessment of cost-effectiveness analysis of pharmaceutical therapies for advanced colorectal cancer. 2013 , 47, 506-18	12
401	Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. 2013 , 18, 325-37	76
400	Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies. 2013 , 22, 1567-76	55
399	Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. 2013 , 6, 724-31	61
398	Cost-effectiveness analysis: comparing single-level cervical disc replacement and single-level anterior cervical discectomy and fusion: clinical article. 2013 , 19, 546-54	66
397	Utility-based quality of life associated with overweight and obesity: the Australian diabetes, obesity, and lifestyle study. 2013 , 21, 652-5	22
396	Is liver transplantation using organs donated after cardiac death cost-effective or does it decrease waitlist death by increasing recipient death?. 2013 , 15, 182-9	8
395	Utility values in the visually impaired: comparing time-trade off and VisQoL. 2013 , 90, 843-54	3
394	The societal and economic value of rotator cuff repair. 2013 , 95, 1993-2000	237
393	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. 2013 , 16, 713-9	13
392	Patient time costs associated with sensor-augmented insulin pump therapy for type 1 diabetes: results from the STAR 3 randomized trial. 2013 , 33, 215-24	8
391	Societal and economic impact of anterior cruciate ligament tears. 2013 , 95, 1751-9	259

390	Cost-effectiveness of internet and telephone treatment for smoking cessation: an economic evaluation of The iQUITT Study. 2013 , 22, e11	30
389	The role of pain in understanding racial/ethnic differences in the frequency of physical activity among older adults. 2013 , 25, 405-21	16
388	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. 2013 , 29, 117-22	191
387	More donors or more delayed graft function? A cost-effectiveness analysis of DCD kidney transplantation. 2013 , 27, 289-96	23
386	Resource utilization and cost analyses of home-based palliative care service provision: the Niagara West End-of-Life Shared-Care Project. 2013 , 27, 115-22	26
385	Cost-effectiveness of population-based screening for colorectal cancer. 2013 , 108, 1209-10	2
384	Cost collection and analysis for health economic evaluation. 2013 , 149, 192-9	16
383	Using decision analysis to assess comparative clinical efficacy of surgical treatment of unstable ankle fractures. 2013 , 27, 642-8	13
382	Evaluating the economics of complementary and integrative medicine. 2013 , 2, 56-63	14
381	How methodologic differences affect results of economic analyses: a systematic review of interferon gamma release assays for the diagnosis of LTBI. 2013 , 8, e56044	20
380	Critical Appraisal of Pharmacoeconomic Studies. 2014 , 62-65	
379	Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. 2014 , 7, 341-50	23
378	Stress ulcer prophylaxis: it's that same old wine in a brand new bottle*. 2014 , 42, 979-80	1
377	Evaluation of cost-utility in middle ear implantation in the 'Nordic School': a multicenter study in Sweden and Norway. 2014 , 134, 19-25	10
376	The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. 2014 , 11 Suppl 2, S105-11	22
375	Long-term utility outcomes in patients undergoing endoscopic sinus surgery. 2014 , 124, 19-23	64
374	Antiretroviral therapy recommendations for the global community: aspiration versus reality. 2014 , 28, 939-41	3
373	Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load. 2014 , 123, 929-937	21

372	Should patients with ocular genetic disorders have genetic testing?. 2014 , 25, 359-65	5
371	The 5-year cost-effectiveness of anterior cervical discectomy and fusion and cervical disc replacement: a Markov analysis. 2014 , 39, 1924-33	40
370	Consensus guidelines for the management of postoperative nausea and vomiting. 2014 , 118, 85-113	930
369	Tutorial on health economics and outcomes research in nutrition. 2014 , 38, 5S-16S	4
368	Second-line agents for glycemic control for type 2 diabetes: are newer agents better?. 2014 , 37, 1338-45	50
367	Cost-effectiveness of femtosecond laser-assisted cataract surgery versus phacoemulsification cataract surgery. 2014 , 121, 10-16	72
366	Cost-effectiveness of competing strategies for management of recurrent <i>Clostridium difficile</i> infection: a decision analysis. 2014 , 58, 1507-14	107
365	Economic evaluation of access to musculoskeletal care: the case of waiting for total knee arthroplasty. 2014 , 15, 22	20
364	Pharmacologic regimens for knee osteoarthritis prevention: can they be cost-effective?. 2014 , 22, 415-30	15
363	Echocardiography screening of siblings of children with bicuspid aortic valve. 2014 , 133, e1212-7	25
362	Making the case for cost-effectiveness research. 2014 , 109, 509-15	9
361	Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. 2014 , 40, 676-85	29
360	Endocrine scintigraphy with hybrid SPECT/CT. 2014 , 35, 717-46	10
359	Meta- and cost-effectiveness analysis of commercial weight loss strategies. 2014 , 22, 1942-51	105
358	How to report a research study. 2014 , 21, 1088-116	3
357	Cost-effectiveness of a package of interventions for expedited antiretroviral therapy initiation during pregnancy in Cape Town, South Africa. 2014 , 18, 697-705	15
356	Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria. 2014 , 275, 304-16	43
355	Cost-Effectiveness Analysis of Early Reconstruction Versus Rehabilitation and Delayed Reconstruction for Anterior Cruciate Ligament Tears. 2014 , 42, 1583-91	55

354	Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt. 2014 , 58, 1064-71	31
353	Economic evaluations of guideline-based or strategic interventions for the prevention or treatment of chronic wounds. 2014 , 12, 373-89	20
352	Do changes in drug coverage policy point to an increased role for cost-effectiveness analysis in the USA?. 2014 , 32, 729-33	7
351	Comparison of complementary and alternative medicine with conventional mind-body therapies for chronic back pain: protocol for the Mind-body Approaches to Pain (MAP) randomized controlled trial. 2014 , 15, 211	18
350	Yoga vs. physical therapy vs. education for chronic low back pain in predominantly minority populations: study protocol for a randomized controlled trial. 2014 , 15, 67	40
349	Economic evaluation in health care: a modern day quagmire. 2014 , 33, 344-6	0
348	Using time trade-off methods to assess preferences over health care delivery options: a feasibility study. 2014 , 17, 302-5	8
347	Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. 2014 , 79, 455-65	59
346	Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis. 2014 , 121, 1855-62	36
345	Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial. 2014 , 15, 502	7
344	Constrained resources. 237-299	1
343	Cost-effectiveness of stereotactic radiosurgery with and without whole-brain radiotherapy for the treatment of newly diagnosed brain metastases. 2014 , 121 Suppl, 84-90	53
342	Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions. 2014 , 19, 425-36	37
341	A methodological analysis of the plastic surgery cost-utility literature using established guidelines. 2014 , 133, 584e-592e	3
340	Guiding the Development and Use of Cost-Effectiveness Analysis in Education. 2015 , 8, 400-418	56
339	Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. 2015 , 125, 1866-9	27
338	The Quality of Cost-Utility Analyses in Orthopedic Trauma. 2015 , 38, e673-80	21
337	Redefining Overuse to Include Costs: A Decision Analysis for Computed Tomography in Minor Head Injury. 2015 , 41, 313-22	6

336	Medicare Chronic Care Management Payments and Financial Returns to Primary Care Practices: A Modeling Study. 2015 , 163, 580-8	36
335	Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis. 2015 , 1, 22	4
334	The Value of Restaging With Chest and Abdominal CT/MRI Scan After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. 2015 , 94, e2074	3
333	A systematic review on the affordability of a healthful diet for families in the United States. 2015 , 32, 68-80	26
332	Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation. 2015 , 28, 1055-65	7
331	Making a case for high-volume robotic surgery centers: A cost-effectiveness analysis of transoral robotic surgery. 2015 , 112, 155-63	29
330	Economic analysis of rapid and sensitive polymerase chain reaction testing in the emergency department for influenza infections in children. 2015 , 34, 577-82	49
329	Cost-Effectiveness of a Biodegradable Compared to a Titanium Fixation System in Maxillofacial Surgery: A Multicenter Randomized Controlled Trial. 2015 , 10, e0130330	9
328	Cost-effective analysis of unilateral vestibular weakness investigation. 2015 , 36, 277-81	13
327	The cost-effectiveness of surgical treatment of medial unicompartmental knee osteoarthritis in younger patients: a computer model-based evaluation. 2015 , 97, 807-17	39
326	The Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn's Disease Patients with Adalimumab Non-response in the USA. 2015 , 9, 669-75	10
325	Sustainability of behavioral interventions: beyond cost-effectiveness analysis. 2015 , 22, 425-33	53
324	Updating Cost Effectiveness Analyses in Orthopedic Surgery: Resilience of the \$50,000 per QALY Threshold. 2015 , 30, 1118-20	40
323	Cost-Benefit and Cost-Effectiveness Analyses in Evaluation Research. 2015 , 55-62	2
322	The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis. 2015 , 162, 474-84	49
321	Evaluating an extended rehabilitation service for stroke patients (EXTRAS): study protocol for a randomised controlled trial. 2015 , 16, 205	11
320	The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology. 2015 , 15, 931-40	16
319	HIQA's CEA of Breast Screening: Pragmatic Policy Recommendations are Welcome, but ACERs Reported as ICERs are Not. 2015 , 18, 941-5	5

318	Efficacy and cost-effectiveness of immediate surgery versus a wait-and-see strategy for sporadic nonfunctioning T1 pancreatic endocrine neoplasms. 2015 , 101, 25-34	8
317	Cost-effectiveness analyses in orthopaedic sports medicine: a systematic review. 2015 , 43, 1530-7	43
316	Cost-effectiveness of the endoscopic versus microscopic approach for pituitary adenoma resection. 2015 , 125, 16-24	24
315	Economic analysis of continuous antibiotic prophylaxis for prevention of urinary tract infections in infants with high-grade hydronephrosis. 2015 , 11, 247.e1-8	3
314	Cost comparison of transcatheter and operative closures of ostium secundum atrial septal defects. 2015 , 169, 727-735.e2	23
313	Cost Effectiveness of a Sugar-Sweetened Beverage Excise Tax in the U.S. 2015 , 49, 112-23	122
312	Understanding Cost-Effectiveness Analyses: An Explanation Using Three Different Analyses of Lung Cancer Screening. 2015 , 205, 344-7	3
311	Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model. 2015 , 158, 339-48	20
310	BMI and Healthcare Cost Impact of Eliminating Tax Subsidy for Advertising Unhealthy Food to Youth. 2015 , 49, 124-34	25
309	Liver Resection for Advanced Intrahepatic Cholangiocarcinoma: A Cost-Utility Analysis. 2015 , 39, 2500-9	14
308	An Introduction to Clinical Significance in Orthopaedic Outcomes Research. 2015 , 3,	18
307	Cost Effectiveness of Childhood Obesity Interventions: Evidence and Methods for CHOICES. 2015 , 49, 102-11	74
306	Detecting Germline PTEN Mutations Among At-Risk Patients With Cancer: An Age- and Sex-Specific Cost-Effectiveness Analysis. 2015 , 33, 2537-44	12
305	Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals. 2015 , 121, 1088-97	35
304	Quantifying long-term care preferences. 2015 , 35, 106-13	25
303	The changing face of the cost-utility literature, 1990-2012. 2015 , 18, 271-7	71
302	Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation. 2015 , 12, 1565-73	28
301	Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus. 2015 , 29, 51-63	9

300	Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. 2015 , 18, 161-72	371
299	Comparative effectiveness of home blood pressure telemonitoring (HBPTM) plus nurse case management versus HBPTM alone among Black and Hispanic stroke survivors: study protocol for a randomized controlled trial. 2015 , 16, 97	7
298	The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema. 2015 , 122, 1416-25	24
297	The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. 2015 , 39, 1474-84	30
296	The State of Cost-Utility Analyses in Asia: A Systematic Review. 2015 , 6, 7-13	11
295	OARSI Clinical Trials Recommendations: Key analytic considerations in design, analysis, and reporting of randomized controlled trials in osteoarthritis. 2015 , 23, 677-85	19
294	Cost-effectiveness of genotype testing for primary resistance in Brazil. 2015 , 68, 152-61	11
293	Cost-utility analyses in spine care: a qualitative and systematic review. 2015 , 40, 31-40	21
292	Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions. 2015 , 33, 777-81	3
291	The cost-effectiveness of the Olweus Bullying Prevention Program: Results from a modelling study. 2015 , 45, 127-37	29
290	Three Interventions That Reduce Childhood Obesity Are Projected To Save More Than They Cost To Implement. 2015 , 34, 1932-9	97
289	Laparoscopic Distal Pancreatectomy in Benign or Premalignant Pancreatic Lesions: Is It Really More Cost-Effective than Open Approach?. 2015 , 19, 1415-24	30
288	Can Positive Resection Margin of Intra-hepatic Cholangiocarcinoma Still Provide a Survival Benefit over Systemic Chemotherapy?. 2015 , 39, 2965-6	1
287	What Are the Strength of Recommendations and Methodologic Reporting in Health Economic Studies in Orthopaedic Surgery?. 2015 , 473, 3289-96	8
286	Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography. 2015 , 110, 1298-304	53
285	Dollars and sense. 2015 , 43, 1313-5	1
284	Cost-effectiveness analysis of the diagnosis of meniscus tears. 2015 , 43, 128-37	28
283	Economic evaluation of endoscopic sinus surgery versus continued medical therapy for refractory chronic rhinosinusitis. 2015 , 125, 25-32	79

282	Economic assessment of nutritional recommendations. 2015 , 39, 188-210	32
281	Postoperative nausea and vomiting management: cost-effectiveness and patient outcome. 146-155	
280	Dynamic Assessment of Value During High-Cost Cancer Treatment: A Response to American Society of Clinical Oncology and European Society of Medical Oncology. 2016 , 12, 1215-1218	2
279	Medical costs and quality-adjusted life years associated with smoking: a systematic review. 2016 , 16, 646	13
278	Cost-effective Decisions in Detecting Silent Common Bile Duct Gallstones During Laparoscopic Cholecystectomy. 2016 , 263, 1164-72	11
277	A Cost-Utility Assessment of Mesh Selection in Clean-Contaminated Ventral Hernia Repair. 2016 , 137, 647-659	41
276	SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES. 2016 , 36, 285-98	33
275	Clinical Decision Analysis and Markov Modeling for Surgeons: An Introductory Overview. 2016 , 264, 268-74	17
274	Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors. 2016 , 2, 186-199	3
273	Cost-effectiveness Analysis of Follow-up Strategies for Thunderclap Headache Patients With Negative Noncontrast CT. 2016 , 23, 243-50	14
272	Economic analyses of stress urinary incontinence surgical procedures in women. 2016 , 35, 1040-1045	9
271	Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis. 2016 , 6, 582-9	22
270	Is effectiveness sufficient to choose an intervention?. 2016 ,	10
269	Guidelines for reporting health economic research. 2016 , 98-B, 147-51	9
268	Surgical Management of the Elderly With Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. 2016 , 79, 418-25	13
267	Comparative cost-effectiveness of non-invasive imaging tests in patients presenting with chronic stable chest pain with suspected coronary artery disease: a systematic review. 2016 , 2, 245-260	19
266	Comparison of Costs and Clinical Outcomes Between Hospital and Outpatient Administration of Omalizumab in Patients With Severe Uncontrolled Asthma. 2016 , 52, 211-216	1
265	Are we operating too late? Mortality Analysis and Stochastic Simulation of Costs Associated with Bariatric Surgery: Reconsidering the BMI Threshold. 2016 , 26, 219-28	3

264	Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness. 2016 , 15, e65-74	17
263	New Strategies to Prioritize Nutrition, Physical Activity, and Obesity Interventions. 2016 , 51, e145-e150	9
262	Establishing Cost-Effective Allocation of Proton Therapy for Breast Irradiation. 2016 , 95, 11-18	30
261	Using Patient-Reported Outcomes for Economic Evaluation: Getting the Timing Right. 2016 , 19, 945-950	17
260	Health-Related Quality of Life Trajectories of Extremely Low Birth Weight Survivors into Adulthood. 2016 , 179, 68-73.e1	35
259	Stool DNA Analysis is Cost-Effective for Colorectal Cancer Surveillance in Patients With Ulcerative Colitis. 2016 , 14, 1778-1787.e8	10
258	Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70years of age. 2016 , 143, 453-459	29
257	On the issue of costs in programmatic assessment. 2016 , 5, 303-7	8
256	Is total pancreatectomy as feasible, safe, efficacious, and cost-effective as pancreaticoduodenectomy? A single center, prospective, observational study. 2016 , 20, 1595-607	22
255	Cost-effectiveness of cervical spine clearance interventions with litigation and long-term-care implications in obtunded adult patients following blunt injury. 2016 , 81, 897-904	5
254	Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. 2016 , 3, e000106	39
253	Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. 2016 , 68, 1751-1757	21
252	Endoscopic polypectomy in the clinic: a pilot cost-effectiveness analysis. 2016 , 41, 110-7	10
251	At-Home Versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). 2016 , 31, 1061-7	12
250	The Economic Model of Retinopathy of Prematurity (EcROP) Screening and Treatment: Mexico and the United States. 2016 , 168, 110-121	17
249	Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia. 2016 , 151, 427-439.e6	75
248	Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. 2016 , 48, 798-805	34
247	The Economic Impact of Acetabular Labral Tears: A Cost-effectiveness Analysis Comparing Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Patients Without Osteoarthritis. 2016 , 44, 1771-80	17

246	The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review. 2016 , 5, 6	18
245	Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection. 2016 , 63, 1471-80	33
244	Comparison of Renal Cell Carcinoma Surveillance Guidelines: Competing Trade-Offs. 2016 , 195, 1664-70	11
243	A Simulation Modeling Framework to Optimize Programs Using Financial Incentives to Motivate Health Behavior Change. 2016 , 36, 48-58	10
242	Estimated Cost-Effectiveness of Intensive Interdisciplinary Behavioral Treatment for Increasing Oral Intake in Children With Feeding Difficulties. 2016 , 41, 857-66	12
241	Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age. 2016 , 18, 966-73	28
240	Comparison of Costs and Clinical Outcomes Between Hospital and Outpatient Administration of Omalizumab in Patients With Severe Uncontrolled Asthma. 2016 , 52, 211-6	3
239	Cost-Effectiveness of Lumbar Spendylolisthesis Surgery at 2-Year Follow-up. 2016 , 4, 48-54	5
238	Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. 2016 , 61, 2108-17	44
237	Early Versus Delayed Surgical Decompression of Spinal Cord after Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. 2016 , 88, 166-174	31
236	Introduction to Cost Analysis in IR: Challenges and Opportunities. 2016 , 27, 539-545.e1	8
235	The economic burden of incisional ventral hernia repair: a multicentric cost analysis. 2016 , 20, 819-830	72
234	Budesonide as first-line therapy for non-cirrhotic autoimmune hepatitis in children: a decision analysis. 2016 , 51, 753-62	5
233	Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration. 2016 , 24, 776-85	19
232	Cost effectiveness of bronchial thermoplasty in patients with severe uncontrolled asthma. 2016 , 53, 194-200	25
231	Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. 2016 , 24, 409-18	41
230	Cost-Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis. 2017 , 69, 234-242	25
229	Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis. 2017 , 265, 792-799	25

228	Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. 2017 , 15, e299-e309	20
227	Economic evaluation of future skin cancer prevention in Australia. 2017 , 99, 7-12	23
226	The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited. 2017 , 3, 5	9
225	Weight-loss and exercise for communities with arthritis in North Carolina (we-can): design and rationale of a pragmatic, assessor-blinded, randomized controlled trial. 2017 , 18, 91	9
224	The Cost-Effectiveness of Dual Mobility Implants for Primary Total Hip Arthroplasty: A Computer-Based Cost-Utility Model. 2017 , 99, 768-777	38
223	The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. 2017 , 101, 987-995	16
222	Economic Decision Model for First-Time Traumatic Patellar Dislocations in Adolescents. 2017 , 45, 2267-2275	18
221	Comparative cost-benefit analysis of tele-homecare for community-dwelling elderly in Japan: Non-Government versus Government Supported Funding Models. 2017 , 104, 1-9	4
220	Cost-effectiveness of microsurgical reconstruction for head and neck defects after oncologic resection. 2017 , 39, 541-547	24
219	Laparoscopic Versus Open Cholecystectomy: A Cost-Effectiveness Analysis at Rwanda Military Hospital. 2017 , 41, 1225-1233	12
218	Incremental cost-effectiveness ratio and net monetary benefit: Current use in pharmacoeconomics and future perspectives. 2017 , 43, e36	16
217	Closer to fine: A transition success story. 2017 , 21, e12867	2
216	Cost-effectiveness Analysis of Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Individuals With Hip Labral Tears: Response. 2017 , 45, NP2-NP4	1
215	Cost-effectiveness Analysis Appraisal and Application: An Emergency Medicine Perspective. 2017 , 24, 754-768	19
214	Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement. 2017 , 196, e15-e29	57
213	Cost-Effectiveness of a Clinical Childhood Obesity Intervention. 2017 , 140,	12
212	Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness. 2017 , 123, 4709-4719	18
211	Analyzing cost-effectiveness of neural-monitoring in recurrent laryngeal nerve recovery course in thyroid surgery. 2017 , 48, 180-188	12

210	The Health Economics of the spinal cord injury or disease among veterans of war: A systematic review. 2017 , 40, 649-664	11
209	Evidence of Dietary Improvement and Preventable Costs of Cardiovascular Disease. 2017 , 120, 1681-1688	8
208	Comparison of the levonorgestrel-releasing intrauterine system, hysterectomy, and endometrial ablation for heavy menstrual bleeding in a decision analysis model. 2017 , 139, 121-129	8
207	Effectiveness and Cost-Effectiveness of Endoscopic Screening and Surveillance. 2017 , 27, 397-421	13
206	Treatment of Massive Irreparable Rotator Cuff Tears: A Cost-effectiveness Analysis. 2017 , 40, e65-e76	19
205	International lessons in new methods for grading and integrating cost effectiveness evidence into clinical practice guidelines. 2017 , 15, 1	15
204	Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. 2017 , 123, 3725-3731	51
203	Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. 2017 , 8, e101	79
202	Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. 2017 , 65, 122-133	65
201	Using cost-effectiveness analysis to prioritize policy and programmatic approaches to physical activity promotion and obesity prevention in childhood. 2017 , 95 Suppl, S17-S27	43
200	Suture Button Fixation Versus Syndesmotic Screws in Supination-External Rotation Type 4 Injuries: A Cost-Effectiveness Analysis. 2017 , 45, 210-217	39
199	The Cost-Effectiveness of Anterior Cruciate Ligament Reconstruction in Competitive Athletes. 2017 , 45, 23-33	21
198	Extensive testing or focused testing of patients with elevated liver enzymes. 2017 , 66, 313-319	15
197	Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis with and without nasal polyposis. 2017 , 127, 29-37	30
196	Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. 2017 , 65, 1156-1164	52
195	Cost-utility of HIV Testing Programs Among Men Who Have Sex with Men in the United States. 2017 , 21, 619-625	8
194	Advanced Imaging Adds Little Value in the Diagnosis of Femoroacetabular Impingement Syndrome. 2017 , 99, e133	11
193	Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. 2017 , 4, ofx081	4

192	Differentiated Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings: An Economic Analysis. 2017 , 64, 1724-1730	5
191	Outcomes-Based Reimbursement Policies for Chronic Care Pathways. 2017 ,	7
190	Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States. 2018 , 41, 65-72	16
189	Cost-effectiveness of HIV screening in high-income countries: A systematic review. 2018 , 122, 533-547	19
188	The Seven-Year Cost-Effectiveness of Anterior Cervical Discectomy and Fusion Versus Cervical Disc Arthroplasty: A Markov Analysis. 2018 , 43, 1543-1551	20
187	The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India. 2018 , 21, e25085	9
186	Cost-Effectiveness Analysis of Canagliflozin 300mg Versus Dapagliflozin 10mg Added to Metformin in Patients with Type 2 Diabetes in the United States. 2018 , 9, 565-581	10
185	Simulating results from trials of sigmoidoscopy screening using the OncoSim microsimulation model. 2018 , 15, 52-58	8
184	Value in lumbar spine fusion: Minimally invasive versus traditional open surgery. 2018 , 30, 121-124	
183	Exercise, Manual Therapy, and Booster Sessions in Knee Osteoarthritis: Cost-Effectiveness Analysis From a Multicenter Randomized Controlled Trial. 2018 , 98, 16-27	16
182	Cost-effectiveness of circumferential fusion for lumbar spondylolisthesis: propensity-matched comparison of transforaminal lumbar interbody fusion with anterior-posterior fusion. 2018 , 18, 1969-1973	4
181	Cost-Effectiveness Analysis of Routine Magnetic Resonance Imaging in the Follow-Up of Patients With Nasopharyngeal Carcinoma After Intensity Modulated Radiation Therapy. 2018 , 102, 1382-1391	6
180	The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective. 2018 , 6, 15	13
179	The Cost-Effectiveness of the Kiva Antibullying Program: Results from a Decision-Analytic Model. 2018 , 19, 728-737	21
178	A cost-effectiveness analysis of lowering residential radon levels in Sweden-Results from a modelling study. 2018 , 122, 687-692	6
177	Effects of Arthroscopy for Femoroacetabular Impingement Syndrome on Quality of Life and Economic Outcomes. 2018 , 46, 1205-1213	28
176	HIV screening in pregnant women: A systematic review of cost-effectiveness studies. 2018 , 33, 31-50	11
175	Engaging hepatitis C infected patients in cost-effectiveness analyses: A literature review. 2018 , 67, 774-781	3

174	Assessing Diagnostic Tests. 2018 , 7-37	
173	Cost-Effectiveness of Primary and Revision Surgery for Adult Spinal Deformity. 2018 , 43, 791-797	23
172	The value of frontal sinusotomy for chronic rhinosinusitis with nasal polyps-A cost utility analysis. 2018 , 128, 43-51	9
171	Quality-Adjusted Life Years After Hip and Knee Arthroplasty: Health-Related Quality of Life After 12,782 Joint Replacements. 2018 , 3, e0007	45
170	Cost-Effectiveness of Peer- Versus Venue-Based Approaches for Detecting Undiagnosed HIV Among Heterosexuals in High-Risk New York City Neighborhoods. 2018 , 77, 183-192	4
169	Early Childhood Inpatient Costs of Critical Congenital Heart Disease. 2018 , 203, 371-379.e7	10
168	Cost-effectiveness of revascularization in patients with intermittent claudication. 2018 , 105, 1742-1748	2
167	Cost-Effectiveness Analysis of Intracapsular Tonsillectomy and Total Tonsillectomy for Pediatric Obstructive Sleep Apnea. 2018 , 16, 527-535	3
166	Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?. 2018 , 63, 2094-2104	19
165	Assessment of components included in published societal perspective or QALY outcome economic analyses for antiepileptic drug treatment in chronic epilepsy. 2018 , 18, 487-503	1
164	Biostatistics in Cardiovascular Research with Emphasis on Sex-Related Aspects. 2018 , 1065, 71-92	
163	Cost-Effectiveness Analysis in Radiology: A Systematic Review. 2018 , 15, 1536-1546	8
162	Cost effectiveness and clinical efficacy of patent foramen ovale closure as compared to medical therapy in cryptogenic stroke patients: A detailed cost analysis and meta-analysis of randomized controlled trials. 2018 , 273, 74-79	5
161	Economic costs of hospitalized diarrheal disease in Bangladesh: a societal perspective. 2018 , 3, 1	31
160	Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review. 2018 , 36, 1165-1200	15
159	Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare. 2018 , 62, 673-681	19
158	Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare. 2018 , 113, 1836-1847	10
157	Cost-effectiveness of single-photon emission computed tomography for diagnosis of coronary artery disease: A systematic review of the key drivers and quality of published literature. 2019 , 7, 389-395	0

156	Cost-utility analysis of genetic polymorphism universal screening in colorectal cancer prevention by detection of high-risk individuals. 2019 , 51, 1731-1737	2
155	Interventions to promote healthy environments in family child care homes in Oklahoma-Happy Healthy Homes: study protocol for a randomized controlled trial. 2019 , 20, 541	4
154	Are Patient Self-Reported Outcome Measures Sensitive Enough to Be Used as 'End Points in Clinical Trials?: Evidence from the United Kingdom Glaucoma Treatment Study. 2019 , 126, 682-689	18
153	Cost-effectiveness of HIV care coordination scale-up among persons at high risk for sub-optimal HIV care outcomes. 2019 , 14, e0215965	5
152	Cost-Effectiveness for Surgical Treatment of Degenerative Spondylolisthesis. 2019 , 30, 365-372	3
151	Innovation in Road Freight Transport: Quantifying the Environmental Performance of Operational Cost-Reducing Practices. 2019 , 11, 2212	11
150	What do cost-effective health behaviour-change interventions contain? A comparison of six domains. 2019 , 14, e0213983	10
149	Il est temps d'évaluer le coût-bénéfice de la physiothérapie. 2019 , 19, 1-2	
148	Improving Societal Outcomes in the Organ Donation Value Chain. 2019 , 28, 2110-2131	2
147	Economic evaluations of public health implementation-interventions: a systematic review and guideline for practice. 2019 , 169, 101-113	26
146	Active Surveillance Versus Nephron-Sparing Surgery for a Bosniak IIF or III Renal Cyst: A Cost-Effectiveness Analysis. 2019 , 212, 830-838	16
145	Finding the optimal mix of smoking initiation and cessation interventions to reduce smoking prevalence. 2019 , 14, e0212838	0
144	A head-to-head comparison of EQ-5D-5 L and SF-6D in Chinese patients with low back pain. 2019 , 17, 57	15
143	Rationale and protocol for estimating the economic value of a multicomponent quality improvement strategy for diabetes care in South Asia. 2019 , 4, 7	0
142	Pathology Evaluation of Reduction Mammoplasty Specimens and Subsequent Diagnosis of Malignant Breast Disease: A Claims-Based Analysis. 2019 , 43, 1546-1553	3
141	Cost-utility analysis of colonoscopy or faecal immunochemical test for population-based organised colorectal cancer screening. 2019 , 7, 105-113	8
140	Systematic reviews of health economic evaluations: A structured analysis of characteristics and methods applied. 2019 , 10, 195-206	12
139	Cost-Effectiveness Analysis for Cardiovascular Magnetic Resonance Imaging. 2019 , 568-573.e1	0

138	Immediate Reconstruction of Oncologic Spinal Wounds Is Cost-Effective Compared with Conventional Primary Wound Closure. 2019 , 144, 1182-1195	3
137	The Economic Impact of Flexor Tendon Lacerations of the Hand in the United States. 2019 , 83, 419-423	4
136	Developing the Global Health Cost Consortium Unit Cost Study Repository for HIV and TB: methodology and lessons learned. 2019 , 18, 263-276	9
135	Cost-effectiveness of Pancreatic Cancer Surveillance in High-Risk Individuals: An Economic Analysis. 2019 , 48, 526-536	25
134	Patient-Level Value Analysis: An Innovative Approach to Optimize Care Delivery. 2019 , 33 Suppl 7, S49-S52	5
133	Use of Checklists in Reviews of Health Economic Evaluations, 2010 to 2018. 2019 , 22, 377-382	32
132	Enhancing individual placement and support (IPS) - Supported employment: A Type 1 hybrid design randomized controlled trial to evaluate virtual reality job interview training among adults with severe mental illness. 2019 , 77, 86-97	10
131	Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. 2019 , 18, 65-73	2
130	Long-term quality-adjusted survival following therapeutic bronchoscopy for malignant central airway obstruction. 2019 , 74, 141-156	23
129	Cost-effectiveness of Operative Versus Non-operative Management of Acute Achilles Tendon Ruptures. 2020 , 16, 39-45	5
128	Quality-Adjusted Life-Years Lost Due to Physical Inactivity in a US Population With Osteoarthritis. 2020 , 72, 1349-1357	6
127	Cost-Effectiveness of Exploratory Laparotomy in a Regional Referral Hospital in Eastern Uganda. 2020 , 245, 587-592	3
126	Cost-Effectiveness Analysis of the Surgical Management of Infants Less than One Year of Age with Feeding Difficulties. 2020 , 55, 187-193	2
125	Impact of interventions to reduce overnutrition on healthcare costs related to obesity and type 2 diabetes: a systematic review. 2020 , 78, 412-435	3
124	Mapping the University of Washington Quality of life questionnaire onto EQ-5D and HUI-3 indices in patients with head and neck cancer. 2020 , 42, 513-521	6
123	Biomarkers in Lung Cancer. 2020 , 41, 115-127	19
122	Enhancing vocational training in corrections: A type 1 hybrid randomized controlled trial protocol for evaluating virtual reality job interview training among returning citizens preparing for community re-entry. 2020 , 19, 100604	1
121	Quality of economic evaluations of ventricular assist devices: A systematic review. 2020 , 1-8	0

120	Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. 2020 , 131, 411-448	146
119	Extending Delivery Coverage to Include Prenatal Care for Low-Income, Immigrant Women Is a Cost-Effective Strategy. 2020 , 30, 240-247	3
118	Cost-effectiveness Applications of Patient-reported Outcome Measures (PROMs) in Spine Surgery. 2020 , 33, 140-145	2
117	Cost Analysis of Adjunctive Hydrocortisone Therapy for Septic Shock: U.S. Payer Perspective. 2020 , 48, e906-e911	
116	Some reflections on the use of inappropriate comparators in CEA. 2020 , 18, 29	4
115	Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States. 2020 , 3, e2015756	8
114	Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China. 2020 , 15, e0232240	7
113	Long-term clinical and economic outcomes of a short-term physical activity program in knee osteoarthritis patients. 2020 , 28, 735-743	5
112	Robustness of risk-based allocation of resources for disease prevention. 2020 , 29, 3511-3524	
111	Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancer. 2020 , 42, 2277-2286	6
110	Time-Driven Activity-Based Costing to Model Cost Utility of Enhanced Recovery after Surgery Pathways in Microvascular Breast Reconstruction. 2020 , 230, 784-794.e3	12
109	Cost-effectiveness and quality of life analysis of laparoscopic and robotic distal pancreatectomy: a propensity score-matched study. 2021 , 35, 1420-1428	15
108	Cost-effectiveness analyses in shoulder arthroplasty: a critical review using the Quality of Health Economic Studies (QHES) instrument. 2021 , 30, 1007-1017	2
107	Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. 2021 , 4, e2033787	0
106	Cost-effectiveness analysis of preloaded versus non-preloaded Descemet membrane endothelial keratoplasty for the treatment of Fuchs endothelial corneal dystrophy in an academic centre. 2021 ,	2
105	The financial burden on families of infants requiring neonatal intensive care. 2021 , 45, 151394	3
104	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. 2021 , 22, 723-733	2
103	The Economic Impact of Extensor Tendon Lacerations of the Hand in the United States. 2021 ,	

102	The Cost-Effectiveness of Surgical Intervention for Spinal Metastases: A Model-Based Evaluation. 2021,	0
101	Prophylactic cholecystectomy is not mandatory in patients candidate to the resection for small intestine neuroendocrine neoplasms: a propensity score-matched and cost-minimization analysis. 2021, 1	
100	Optimizing oropharyngeal cancer management by using proton beam therapy: trends of cost-effectiveness. 2021, 21, 944	0
99	Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma. 2021,	0
98	Toward collaborative cost-inclusive evaluation: Adaptations and transformations for evaluators and economists. 2021, 89, 101993	
97	A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment. 2021, 1	1
96	Assessing quality-adjusted years of life lost associated with exclusive cigarette smoking and smokeless tobacco use. 2021, 150, 106707	1
95	Stepwise Approach to the Management of Endometriosis-Related Dysmenorrhea: A Cost-Effectiveness Analysis. 2021, 138, 557-564	0
94	Stepped care for depression at integrated chronic care centers (IC3) in Malawi: study protocol for a stepped-wedge cluster randomized controlled trial. 2021, 22, 630	1
93	Efficacy of Hand Therapy After Volar Locking Plate Fixation of Distal Radius Fracture in Middle-Aged to Elderly Women: A Randomized Controlled Trial. 2021,	1
92	Cost-effectiveness of adrenocorticotrophic hormone versus oral steroids for infantile spasms. 2021, 62, 347-357	5
91	Cost-effectiveness Analysis of Anatomic vs Functional Index Testing in Patients With Low-Risk Stable Chest Pain. 2020, 3, e2028312	8
90	Economics of Hematopoietic Growth Factors. 2004, 409-443	5
89	Cost-effectiveness of venous thromboembolism prophylaxis after total hip replacement. 2002, 17, 126-133	2
88	The Application and Implications of Novel Deterministic Sensitivity Analysis Methods. 2021, 39, 1-17	7
87	Venous thromboembolism prophylaxis after trauma: dollars and sense. 2001, 29, 1839-40	6
86	Methodologic principles of cost analyses in the nursing, medical, and health services literature, 1990-1996. 1999, 48, 94-104	24
85	Outcome assessment in cardiac rehabilitation. Health-related quality of life and economic evaluation. 1997, 17, 179-94	34

84	Pharmaceuticals--cost or investment? An employer's perspective. 2000 , 42, 338-51	20
83	The Influence of Insurance Type on Management of Carpal Tunnel Syndrome: An Analysis of Nationwide Practice Trends. 2016 , 138, 1041-1049	8
82	Quantitative analysis of sponsorship bias in economic studies of antidepressants. 2003 , 183, 498-506	102
81	Can delivery systems use cost-effectiveness analysis to reduce healthcare costs and improve value?. 2016 , 5,	3
80	Cost-Effectiveness of Antivenoms for Snakebite Envenoming in 16 Countries in West Africa. 2016 , 10, e0004568	22
79	An economic evaluation of a video- and text-based computer-tailored intervention for smoking cessation: a cost-effectiveness and cost-utility analysis of a randomized controlled trial. 2014 , 9, e110117	33
78	HIV cure strategies: how good must they be to improve on current antiretroviral therapy?. 2014 , 9, e113031	17
77	Expenditure Analysis of HIV Testing and Counseling Services Using the Cascade Framework in Vietnam. 2015 , 10, e0126659	10
76	Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score. 2016 , 11, e0147237	32
75	Global Patterns of QALY and DALY Use in Surgical Cost-Utility Analyses: A Systematic Review. 2016 , 11, e0148304	11
74	Economic Analysis of Children's Surgical Care in Low- and Middle-Income Countries: A Systematic Review and Analysis. 2016 , 11, e0165480	48
73	Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms. 2020 , 115, 1642-1649	17
72	Expanded HTA: Enhancing Fairness and Legitimacy. 2015 , 5, 1-3	39
71	Economic evaluation in orthopaedics. 2003 , 85, 129-42	57
70	LUMBAR DISC DISORDERS AND LOW-BACK PAIN. 2006 , 88, 21-24	78
69	An Economic Analysis of the Timing of Microsurgical Reconstruction in Brachial Plexus Birth Palsy. 2007 , 89, 970-978	7
68	Economical analysis on prophylaxis, diagnosis, and treatment of periprosthetic infections. 2013 , 7, 227-42	15
67	Replacing ambulatory surgical follow-up visits with mobile app home monitoring: modeling cost-effective scenarios. 2014 , 16, e213	63

66	The effect of mobile app home monitoring on number of in-person visits following ambulatory surgery: protocol for a randomized controlled trial. 2015 , 4, e65	15
65	Cost-effectiveness analysis of beta-blockers vs endoscopic surveillance in patients with cirrhosis and small varices. 2014 , 20, 10464-9	5
64	A Systematic Review of the Economic Evaluation of Telemedicine in Japan. 2016 , 49, 183-96	30
63	Cost Analysis of Diffusion Tensor Imaging and MR Tractography of the Brain. 2014 , 04, 260-269	3
62	The quality of reporting in published cost-utility analyses, 1976-1997. 2000 , 132, 964-72	141
61	Surgeons and Health Services Research. 2001 , 1393-1404	
60	Benchmarking in the ICU: The Measurement of Costs and Outcome to Analyze Efficiency and Efficacy. 2002 , 222-243	1
59	Cost-Effectiveness of Alternatives to Allogeneic Blood Transfusion; Reviewing the Available Evidence. 2002 , 131-142	
58	Issues in the Analysis of Cost-Effectiveness in the Diagnosis and Treatment of Coronary Artery Disease in Women. 2004 , 413-421	
57	COST-UTILITY ANALYSES IN ORTHOPAEDIC SURGERY. 2005 , 87, 1253-1259	1
56	Cost-Effectiveness of Myocardial Perfusion Single-Photon Emission Computed Tomography. 2010 , 400-412	
55	Cost-Effectiveness of Neurostimulation. 2012 , 207-212	
54	Clinical Research in MIS Surgery: Current State and Future Challenges. 2014 , 371-385	
53	Outcomes/Quality Assurance. 1997 , 6, 8-8	
52	Health Economic Analyses of Epilepsy Surgery. 2015 , 255-267	1
51	Improving Societal Outcomes in the Organ Donation Value Chain.	2
50	Cost Analysis of Failed Shoulder Stabilization. 2015 , 5, 14-19	
49	Efficiency and Variance Reduction. 2015 , 256-273	

48	Clinical Decision Making. 639-650	
47	Economic Evaluations. 2017 , 409-426	
46	The Results of the Clinical Trials in Hypertension: Unquestionable Benefits and Limits. 2017 , 9,	1
45	The Role of Predictive Markers in Outcome and Value of Anticancer Drugs in Non-small Cell Lung Cancer. 2018 , 3, 102-104	
44	Writing and Critically Appraising a Scientific Paper. 2019 , 247-260	
43	Animal Health Policy. 2019 , 151-172	
42	Regionally Specific Economic Impact of Screening and Treating Retinopathy of Prematurity in Middle-Income Societies in the Philippines. 2019 , 56, 388-396	0
41	Clinical outcomes and cost-utility of rotator cuff repair surgery by open and arthroscopic techniques: study protocol for a randomised clinical trial. 2020 , 10, e043126	0
40	Pharmacoeconomics. 2020 , 1-135	
39	Health Technology Assessment. Literature Review.. 2020 ,	
38	Multiple Choice Questions with explanations. 1-544	
37	Question 54. 107-108	
36	Cost-Effectiveness of an Adjuvanted Hepatitis B Vaccine (HEPLISAV-B) in Patients With Inflammatory Bowel Disease. 2021 , 3,	0
35	Intensity-modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: A cost-effectiveness analysis. 2021 , 44, 431	0
34	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. 2022 , 129, 336-344	3
33	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. 2022 , 25, 1-7	1
32	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. 2022 , 376, e067975	8
31	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. 2022 , 1	1

30	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force.. 2022 , 25, 10-31	35
29	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. 2022 , 22, 179	2
28	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. 2022 , 1-10	
27	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. 2022 , 22, 114	2
26	Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. 2022 , 38, e13	5
25	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. 2022 , 25, 3-9	14
24	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. 2022 , 3, 100063	2
23	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. 2022 , 20, 23	6
22	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. 2022 , 20, 213	1
21	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. 2022 , 1	1
20	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. 2022 , 28, 146-155	0
19	Cost-effectiveness of Canal Wall-Up vs Canal Wall-Down Mastoidectomy: A Modeling Study.. 2022 , 1945998221076051	
18	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. 2022 ,	2
17	Managing a bone marrow transplant centre to maximise patients' health benefits. 1-25	
16	A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots.. 2022 , 1	0
15	No difference in quality-of-life outcomes in the first 7 years following primary total knee arthroplasty performed using computer navigation versus conventional referencing: A propensity score-matched analysis.. 2022 ,	
14	Overview of Health Economics. 2022 , 1-18	
13	A Telehealth and Telepsychiatry Economic Cost Analysis Framework: Scoping Review.	2

12 A review of caregiver costs included in cost-of-illness studies. 1-10

11 A Cost-Effectiveness Study Comparing Ready-to-Administer and Traditional Vial-and-Syringe Method for Opioids.

10 A Systematic Review of Economic Evaluations Conducted for Interventions to Screen, Treat, and Manage Retinopathy of Prematurity (ROP) in the United States, United Kingdom, and Canada. 1-8

9 Universal First-Trimester Cytomegalovirus Screening and Valaciclovir Prophylaxis in Pregnant Persons: A Cost-Effectiveness Analysis. **2022**, 100676

1

8 Cost-Effectiveness of Arthroscopic Partial Meniscectomy and Physical Therapy for Degenerative Meniscal Tear.

7 Examining the Implementation of Conditional Financial Incentives Using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) Framework to Improve HIV Outcomes among Persons Living with HIV (PLWH) in Louisiana. **2022**, 19, 9486

6 The Cost Utility of Virtual Surgical Planning and Computer-Assisted Design/Computer-Assisted Manufacturing in Mandible Reconstruction Using the Free Fibula Osteocutaneous Flap.

5 Cost-effectiveness of open repair of abdominal aortic aneurysms with a novel peri-operative protocol. **2022**,

0

4 Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.

1

3 Pharmacoeconomics. **2022**, 101-234

0

2 Introduction to Cost-Effectiveness Analysis. **2013**, 1795-1801.e1

0

1 Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis. **2023**, 77, 1702-1711

0